CD274 and non-small cell lung carcinoma: ICIs that block PD-1/PD-L1 axis have demonstrated improvements in survival over chemotherapy alone in NSCLC in multiple randomized trials both when administered as individual agents (1–3) and as combination ICI regimens (4).